Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.

about

Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment.

Item

http://www.wikidata.org/entity/Q50169188

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Characteristics of patients wi ...... ble for second-line treatment.

@en

Characteristics of patients wi ...... ble for second-line treatment.

@nl

type

Item

label

Characteristics of patients wi ...... ble for second-line treatment.

@en

Characteristics of patients wi ...... ble for second-line treatment.

@nl

prefLabel

Characteristics of patients wi ...... ble for second-line treatment.

@en

Characteristics of patients wi ...... ble for second-line treatment.

@nl

P1476

Characteristics of patients wi ...... ble for second-line treatment.

@en

P2093

Akinobu Tawada

http://www.w3.org/2001/XMLSchema#string

Eiichiro Suzuki

http://www.w3.org/2001/XMLSchema#string

Hitoshi Maruyama

http://www.w3.org/2001/XMLSchema#string

Kazufumi Kobayashi

http://www.w3.org/2001/XMLSchema#string

Makoto Arai

http://www.w3.org/2001/XMLSchema#string

Masanori Inoue

http://www.w3.org/2001/XMLSchema#string

Masato Nakamura

http://www.w3.org/2001/XMLSchema#string

Masayuki Yokoyama

http://www.w3.org/2001/XMLSchema#string

Naoya Kato

http://www.w3.org/2001/XMLSchema#string

Osamu Yokosuka

http://www.w3.org/2001/XMLSchema#string

P2860

JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan

Management of hepatocellular carcinoma: An update

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

Sorafenib in advanced hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Prospective study of transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: an Asian cooperative study between Japan and Korea.

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

P2888

s10637-017-0507-3

P31

scholarly article

P356

10.1007/S10637-017-0507-3

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28891038

http://www.w3.org/2001/XMLSchema#string